Relevium Selects 93,000 Sq. Ft Organic Cultivation Facility in Quebec
Momentum Public Relations
Press Release: June 4 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that, through its wholly-owned subsidiary Biocannabix (“BCX”), it has selected a 93,000 square foot facility in Montreal, Quebec with the objective of cultivating premium organic cannabis.
With the assistance of PipeDreemz Inc., Relevium has conducted initial assessment on the facility, a 93,000 Sq. Ft industrial building located adjacent to the TransCanada Highway, Trudeau International Airport and about 20 minutes from downtown Montreal. The building has been selected as a desirable location with a low risk profile for the application submission to Health Canada for an ACMPR cultivation license. Biocannabix will be leveraging the vast experience of lead consultant George Routhier and his company PipeDreemz Inc., a company with a remarkable 100% rate of success with ACMPR licensing from Health Canada.
Company Strategy
The strategy for the Company is to cultivate high quality organic strains for use in exclusive, high-end consumer packaged goods primarily for health and wellness. The Company will not compete on large scale supply, but rather plans to focus on custom niche and organic products with established partnerships for processing and ongoing research in cannabis derivatives.
The Company intends to develop the project in stages and expects to retrofit the building with an initial phase of 10,000 Sq. Ft of cultivation. Upon the completion of the first stage, successful operations and licensing, the company will then proceed with phases 2 and 3. Construction of the project is subject to financing and customary approvals.
Aurelio Useche, CEO of Relevium stated: “The strategy of Biocannabix will not be catered around being the lowest cost producer, but rather on being a premium and custom producer focused on consumer packaged goods to be sold through Relevium’s current and new brands.” Mr. Useche stated further: “The value in the supply chain will be in developing trusted, unique, ultra-premium product for luxurious brands.”
About PipeDreemz
The founder and CEO of PipeDreemz, George Routhier has over 15 years of experience in Medical Marijuana research and 8 years of experience as a designated grower under MMAR. PipeDreemz is one of the most senior consultants in the Canadian cannabis landscape and has helped clients obtain over 16 Licensed Producers since inception. PipeDreemz offers a turnkey, start to finish service and has never had a Licensed Producer application fail at Health Canada.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Announces Revenue of $3.2M for the Nine-Month Period Ended March 31, 2018
Momentum Public Relations
Press Release: May 30 2018
Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”) is pleased to announce its financial and operating results for the three and nine months’ period ended March 31, 2018.
Highlights
- Nine-month sales totalled $3,157,644 including Q3 sales of $1,063,176 recorded by Bioganix®
- Nine-month gross profit of $1,806,515 (57%), including Q2 gross profit of $575,495 (56%)
- In this reporting period, the Company:
- Initiated a market test for the eventual launch of a complete Aloe Vera based health support products and cosmetics
- Revealed a new brand architecture for Bioganix®
- Conducted the initial joint-launch of Planet Hemp with HEMPCO
- Established its presence for the European marketplace in partnership with Amazon
- The Company increased product offerings by 17% to 38 products with further plans to expand to over 50 products in 2018
Results from Operations
During the nine-month period ended March 31, 2018, the Bioganix brand generated $3,157,644 in sales revenues with a gross profit of $1,806,515. A gross margin of 57% continues to remain stable and adjusted EBITDA for the brand remains positive at 25%. On a consolidated basis, the Company reported an increase in expenses in three key areas:
- Selling and Marketing Expenses: The reporting period was marked by a period of preparation for market expansion, which included increased expenses relating to initiatives to build brand equity, expand geographically, launch of new products and build the operating team. The investments included brand repositioning and branding services, promotions and new product launches, increased digital marketing campaigns and other value-added services. The total marketing expense for the nine-month was reported at $1,252,668 with $313,167 allocated to market expansion, branding and product launch initiatives.
- Interest and Accretion Expenses: The Company reported a total of $612,040 ($348,422 of interest and $263,618 of accretion) in the nine-month reporting period for servicing the long-term convertible debt currently on the balance sheet.
- Share-based compensation: The Company reported $554,110 non-cash share-based compensation, reflecting stock options issued to directors, consultants and management in the reporting nine-month period.
These three key areas represent $2,418,818 or 67% of all the Company’s operating expenses for the nine-month reporting period. The Company reported net and comprehensive losses of $1,787,985 ($566,070 in 2017) and Adjusted Earnings Before Interest, Taxes and Amortization totaling $384,151 in the same period.
Aurelio Useche, President and CEO of Relevium stated: “We have increased our marketing and sales spend significantly to successfully launch a new brand, new products and to expand into new markets as previously announced.” Mr. Useche stated further: “Revenues from the original Bioganix product line remain as expected and believe that the additional investments will bear fruit once our presence in Amazon UK and Walmart.com is strong and the new products have taken hold within our customer base.”
For more information, the Company’s previous filings may be reviewed by visiting www.sedar.com and also our website www.releviumtechnologies.com.
Adjusted EBITDA and Non-IFRS Financial Measures
The Management Discussion and Analysis for the same period includes certain measures which are not defined terms in accordance with IFRS such as Adjusted EBITDA. The term “Adjusted EBITDA” refers to net income or net loss after adjusting for interest, taxes, depreciation and costs relating to acquisitions and their integration.
The Company believes that Adjusted EBITDA is useful, supplemental information as it provides an indication of the results generated by the company’s main business activities prior to taking into consideration how those activities are financed and taxed and prior to taking into consideration depreciation and particularly the costs of integration of acquisitions.
Adjusted EBITDA is also a key measure used by the Company’s management and its Board of Directors to understand and evaluate the Company’s operating performance, to prepare annual budgets, and to help develop operating plans. Adjusted EBITDA is not a measure of performance under IFRS and should not be considered in isolation or as a substitute for net and comprehensive income or loss prepared in accordance with IFRS or as a measure of operating performance or profitability.
Adjusted EBITDA does not have a standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
See “Adjusted EBITDA and Non-IFRS Financial Measures”
- Published in Relevium Technologies
Relevium Launches Bioganix® on Walmart.com
Momentum Public Relations
Press Release: May 3 2018
Relevium TechnologiesInc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce that it has received approval to sell its biggest mover Bioganix® products on Walmart.com.
Highlights
- New and diverse revenue channel with over 400M monthly visitors
- Onboarding and approval to Walmart.com is complete
- Sales testing of Bioganix® products is currently online
- Bioganix® will launch best selling SKUs and customize a new offering for a new demographic
- Opens a new sales vertical and mitigates channel risk
Walmart.com will provide Relevium with access to 400M new visitors per month with a diverse customer demographic and profile. According to CBS MoneyWatch, Walmart.com shoppers are primarily young women and nearly half have families with kids and a diverse ethnic profile. Amazon and Walmart demographics are complementary thereby mitigating channel risk for the Bioganix® brand.
Aurelio Useche, CEO of Relevium stated: “The addition of the Walmart.com platform to the existing Amazon.com sales channel gives Bioganix® a new and diverse audience and should prove to be accretive to revenues going forward.” Mr. Useche continued: “Diversifying our sales channels also de-risks the reliance on individual marketplaces and allows us to reach new customers across the USA, Europe and Asia. This is a major step for the Company and our expectations are high.”
Abis Hussain, SMO of Relevium, stated: “The Operations Team has concluded that the audience and the competition on Walmart.com is very different than those in Amazon.com and should reflect nicely on the bottom line for the Company. As an added bonus, Walmart.com will be key to the introduction of full spectrum hemp oil products, which will prove to be extremely valuable going forward as we prepare to launch products related to the space.”
Bioganix® products have been available on the Walmart.com platform, on a test-basis, for sale and delivery in the United States of America as of May 1, 2018. Initially, the Company will be offering five (5) to eight (8) of its best-selling products on the platform and then evaluate which products will subsequently be made available.
Relevium has the intention of selling products from its current catalogue as well as new products that will be launched in 2018. New products will be centered around major themes in the health and wellness markets including weight management, sports performance, ketogenic diets and general well being offered through hemp-derived products.
Bioganix® products will now be widely available in the USA through Bioganix.com, Amazon.com and Walmart.com and imminently in the United Kingdom through Amazon.co.uk.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Announces Agreement with Neptune Wellness for MaxSimil®
Momentum Public Relations
Press Release: April 30, 2019
Relevium Technologies Inc. (TSX.V:RLV), (OTCQB:RLLVF) and (Frankfurt:6BX) (the“Company” or “Relevium”), is pleased to announce the signing of a product development, supply and commercialization agreement with Neptune Wellness Solutions (TSX:NEPT) (NASDAQ:NEPT) for MaxSimil®, a patented fish oil monoglyceride omega 3 technology.
Highlights
- MaxSimil® is a technology that enhances the absorption of lipid and lipid-soluble ingredients in the production of nutraceuticals
- The agreement includes product development, supply and commercialization for Canada and USA
- Initial 2-year term
- Development of two (2) products in year one and an additional six (6) within year two
- The agreement includes Research and Development contribution by Relevium in the form of a 2.5% royalty on net sales payable to Neptune quarterly
Aurelio Useche, Relevium’s CEO “We are very pleased to partner with Neptune Wellness to develop new formulations combining MaxSimil® technology with plant derivatives and other nutraceutical ingredients, which will form part of current and future exclusive science-based brands” Mr. Useche continued: “The MaxSimil technology could prove to be a real differentiator for products marketed through our subsidiaries BGX Health and Biocannabix Health and their brands”
Francois-Karl Brouillette, Neptune’s VP, Science and Innovation stated:” Relevium’s business and product development strategies will be great accelerators to Neptune’s own MaxSimil® nutraceutical development program. Free of any unwanted excipients and mimicking our natural biological system, MaxSimil technology is an efficient nutraceutical-type delivery system that is perfectly compatible with today’s dietary supplement industry.” Mr. Brouillette added: “I strongly believe that this exciting new partnership will help us further unlock this patented technology’s full potential while extending its reach to a broader consumer base.”
About MaxSimil®
MaxSimil is a novel, patented delivery platform that enhances the absorption of lipid-based and lipid-soluble nutraceuticals. MaxSimil mimics the human digestive process to deliver absorption-ready, pre-digested lipid-based products such as plant and fish derived oils.
About Neptune Wellness Solutions
Neptune is a wellness products company, with more than 50 years of combined experience in the industry. The Company formulates and provides turnkey solutions available in various unique delivery forms, offers specialty ingredients such as MaxSimil®, a patented ingredient that may enhance the absorption of lipid-based nutraceuticals, and a variety of other marine and seed oils. Neptune also sells premium krill oil directly to consumers through web sales at www.oceano3.com. Leveraging our scientific, technological and innovative expertise, Neptune is working to develop unique extractions and formulations in high potential growth segments such as medical and wellness cannabinoid-based products. The Company’s head office is located in Laval, Quebec.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses and entrepreneurial brands in the growing health and wellness sector. The Company creates value by building brand equity, organic product offering and geographic expansion. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook, Follow us on Twitter
and Follow us on LinkedIn
- Published in Relevium Technologies
Relevium Announces All-Time Record High of Units Sales for Bioganix(R) in March
Momentum Public Relations
Press Release: April 3 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to report an all-time record high in unit sales for the month of March 2018.
The reported record high of 16,549 units, which was achieved in a seasonally low period, reflects increased online demand for the Bioganix® established product line, which is expected to translate into sales in excess of $439,000 for the month of March. The monthly high did not include the effect from new product launches, which are expected to have an incremental positive impact over the next six months.
The company’s all-time record high of units sold is an important achievement for Relevium’s Bioganix®brand. The Company continues to increase its subscriber base and number of SKUs, now totaling over 230,000 and 38 respectively.
Impact on the Business
- Increase of Bioganix® demand sets the stage for successful launch of new products
- The results indicate that the company’s investment in Mach 2.0 Marketing Engine is starting to pay dividends
Impact on Shareholders
- Increased confidence that management remains engaged on delivering sustainable value to its brands, customers and shareholders
- Incremental value to the acquired Bioganix® business through increased brand equity, exclusive product lines and geographic expansion
- Relevium is steadily building solid base for shareholder value creation, which will deliver future dividends
Abis Hussain, SMO of Relevium, stated: “The implications of this may seem trivial, but the results form this month in a seasonally low period indicate that Mach 2.0 is working as designed. We expect this to also have a positive impact on new products launches over the next six months.”
Aurelio Useche, CEO of Relevium, stated: “This is the first real test of the capabilities of our marketing engine following months of adjustments and beta testing. This small but important success is an important achievement for the company and for our digital marketing and operating teams.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
RELEVIUM TECHNOLOGIES INC
Relevium Technologies Inc.
Aurelio Useche
President and CEO
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies